Drug intelligence / Profile preview

ATX-2286

Development stage: Preclinical
Lead developer: Oxagen
Modality: Small Molecules
Administration: Unknown (no Specific Route Information Found)

Overview

ATX-2286 is a small molecule drug developed by Oxagen Ltd. It acts as an antagonist of CRTH2 (Chemoattractant Receptor-homologous molecule expressed on Th2 cells), also known as Prostaglandin D2 receptor 2. By blocking CRTH2, ATX-2286 modulates immune and inflammatory responses, making it relevant for treating immune system diseases and respiratory diseases such as asthma. The drug is currently in preclinical development stages with no clinical trials reported yet.

Other names: ATX-2286ATX2286ATX 2286OC-2286OC2286OC 2286

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on ATX-2286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX-2286.

Explore the full profile